| Predicate |
Object |
| contentType |
Journal Article |
| endingPage |
765 |
| issn |
0306-9877 |
| issueIdentifier |
4 |
| pageRange |
764-765 |
| publicationName |
Medical Hypotheses |
| startingPage |
764 |
| bibliographicCitation |
Tanvetyanon T. Is hypocalcemia during therapy with zoledronic acid or other bisphosphonates beneficial to cancer patients? Med Hypotheses. 2004;63(4):764–5. doi: 10.1016/j.mehy.2004.06.003. PMID: 15325030. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c2db178719c70017f2d845177ff2b843 |
| date |
200401 |
| identifier |
https://doi.org/10.1016/j.mehy.2004.06.003
https://pubmed.ncbi.nlm.nih.gov/15325030 |
| isPartOf |
https://portal.issn.org/resource/ISSN/0306-9877
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5617 |
| language |
English |
| source |
https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/ |
| title |
Is hypocalcemia during therapy with zoledronic acid or other bisphosphonates beneficial to cancer patients? |
| discusses |
http://id.nlm.nih.gov/mesh/M0003153
http://id.nlm.nih.gov/mesh/M0006519
http://id.nlm.nih.gov/mesh/M0011048
http://id.nlm.nih.gov/mesh/M0234600
http://id.nlm.nih.gov/mesh/M0328153 |
| hasPrimarySubjectTerm |
http://id.nlm.nih.gov/mesh/D006996Q000139
http://id.nlm.nih.gov/mesh/D007093Q000008
http://id.nlm.nih.gov/mesh/D002118Q000378
http://id.nlm.nih.gov/mesh/D009369Q000188
http://id.nlm.nih.gov/mesh/D004164Q000008
http://id.nlm.nih.gov/mesh/D020533Q000008
http://id.nlm.nih.gov/mesh/D009369Q000378
http://id.nlm.nih.gov/mesh/D006996Q000378
http://id.nlm.nih.gov/mesh/D009389Q000188 |
| hasSubjectTerm |
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D008954
http://id.nlm.nih.gov/mesh/D000077211
http://id.nlm.nih.gov/mesh/D016896
http://id.nlm.nih.gov/mesh/D004164Q000009
http://id.nlm.nih.gov/mesh/D007093Q000009 |
| discussesAsDerivedByTextMining |
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID68740
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8118
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 |